Cargando…

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738

Understanding the therapeutic effect of drug dose and scheduling is critical to inform the design and implementation of clinical trials. The increasing complexity of both mono, and particularly combination therapies presents a substantial challenge in the clinical stages of drug development for onco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Checkley, Stephen, MacCallum, Linda, Yates, James, Jasper, Paul, Luo, Haobin, Tolsma, John, Bendtsen, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550834/ https://www.ncbi.nlm.nih.gov/pubmed/26310312 http://dx.doi.org/10.1038/srep13545

Ejemplares similares

Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2016)

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
por: Vendetti, Frank P., et al.
Publicado: (2023)

Dose-Dependent Bioavailability and Tissue Distribution of the ATR Inhibitor AZD6738 (ceralasertib) in Mice
por: Kiesel, Brian F., et al.
Publicado: (2022)

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma
por: Talebpoor, Maryam, et al.
Publicado: (2022)

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
por: Fròsina, Guido, et al.
Publicado: (2018)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting repair of DNA damage
por: Suzuki, Takuya, et al.
Publicado: (2022)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
por: Yap, Timothy A., et al.
Publicado: (2021)

AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells
por: Harata, Shinnosuke, et al.
Publicado: (2023)

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
por: Kwon, Minsuk, et al.
Publicado: (2022)

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
por: Vendetti, Frank P., et al.
Publicado: (2015)

Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells
por: Isono, Makoto, et al.
Publicado: (2022)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways
por: Huang, Longxiang, et al.
Publicado: (2022)

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
por: Dillon, M.T., et al.
Publicado: (2018)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
por: Ring, Alistair, et al.
Publicado: (2023)

Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules
por: Shankaran, Harish, et al.
Publicado: (2017)

Bridging the gap between laboratory and applied research on response‐independent schedules
por: Ingvarsson, Einar T., et al.
Publicado: (2022)

Bridging the gap
Publicado: (2018)

Bridging the gap
por: Armitage, Sarah K, et al.
Publicado: (2016)

Bridging the Gap
por: Halpin, Hilary
Publicado: (1958)

Bridging the Gap
por: Whisenant, Brian, et al.
Publicado: (2023)

Bridging the gap: a review of dose investigations in paediatric investigation plans
por: Hampson, Lisa V, et al.
Publicado: (2014)

Bridging the Values Gap
por: Freeman, R
Publicado: (2015)

Bridging the gap : articles on mexican literature
por: Spell, Jefferson Rea, 1886-
Publicado: (1971)

Therapeutic use of psilocybin: Practical considerations for dosing and administration
por: MacCallum, Caroline A., et al.
Publicado: (2022)

Thrombosis with thrombocytopenia after second dose of AZD-1222
Publicado: (2021)

Bridging the gap: a review of dose-investigation studies in paediatric investigation plans
por: Hampson, Lisa, et al.
Publicado: (2013)

Understanding and bridging the conservation‐genetics gap in marine conservation
por: Sandström, Annica, et al.
Publicado: (2019)

Bridging the gap to university mathematics
por: Hurst, Edward, et al.
Publicado: (2009)

CD23 bridges the gap
por: Van Epps, Heather L.
Publicado: (2005)

Bridging the gap in border health.
por: Booker, S M
Publicado: (2000)

Relationships in the NHS: bridging the gap
por: de Melker, Ruut A.
Publicado: (2001)

Cybersecurity and privacy: bridging the gap
por: Khajuria, Samant, et al.
Publicado: (2017)

Inequality in Training: Bridging the Gap
por: Rambani, Rohit
Publicado: (2020)

Bridging the Family Care Gap
por: Gaugler, Joseph, et al.
Publicado: (2021)

Bridging the gap with bacterial art
por: Frankel, Eve, et al.
Publicado: (2023)

The use of L.S.D. 25 in psychiatry.
por: MacCallum, W. A.
Publicado: (1968)

Cannot write session to /tmp/vufind_sessions/sess_ee1ndmlfdhmbbltolrjlkgemic